Extracellular vesicles: The next generation in gene therapy delivery
Molecular Therapy · 2023-05 · 31 (5) · 1225-1230
DOI: 10.1016/j.ymthe.2023.01.021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2023-05. Verfasst von Riccardo Cecchin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Menzies Health Institute Queensland, School of Pharmacy and Medical Science, Griffith University, Gold Coast Campus, Southport, QLD 4222, Australia. Hauptthemen laut MEDLINE: Extracellular Vesicles, Nanoparticles. Die Arbeit wurde bisher 200-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIDA NIH HHS, NIMH NIH HHS.
Abstract (Originalsprache)
Extracellular vesicles (EVs) are esteemed as a promising delivery vehicle for various genetic therapeutics. They are relatively inert, non-immunogenic, biodegradable, and biocompatible. At least in rodents, they can even transit challenging bodily hurdles such as the blood-brain barrier. Constitutively shed by all cells and with the potential to interact specifically with neighboring and distant targets, EVs can be engineered to carry and deliver therapeutic molecules such as proteins and RNAs. EVs are thus emerging as an elegant in vivo gene therapy vector. Deeper understanding of basic EV biology-including cellular production, EV loading, systemic distribution, and cell delivery-is still needed for effective harnessing of these endogenous cellular nanoparticles as next-generation nanodelivery tools. However, even a perfect EV product will be challenging to produce at clinical scale. In this regard, we propose that vector transduction technologies can be used to convert cells either ex vivo or directly in vivo into EV factories for stable, safe modulation of gene expression and function. Here, we extrapolate from the current EV state of the art to a bright potential future using EVs to treat genetic diseases that are refractory to current therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Menzies Health Institute Queensland, School of Pharmacy and Medical Science, Griffith University, Gold Coast Campus, Southport, QLD 4222, Australia.
- Departments of Molecular and Comparative Pathobiology and Neurology, and Richman Family Precision Medicine Center of Excellence in Alzheimer's Disease, Johns Hopkins University, Baltimore, MD 21205, USA.
- Departments of Molecular and Comparative Pathobiology and Neurology, and Richman Family Precision Medicine Center of Excellence in Alzheimer's Disease, Johns Hopkins University, Baltimore, MD 21205, USA. Electronic addr…
- Menzies Health Institute Queensland, School of Pharmacy and Medical Science, Griffith University, Gold Coast Campus, Southport, QLD 4222, Australia. Electronic address: kevin.morris@griffith.edu.au.
Förderung
- NIAID NIH HHS
- NIDA NIH HHS
- NIMH NIH HHS
- NCI NIH HHS
- National Institute of Mental Health
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Cecchin, R., Troyer, Z., Witwer, K., & Morris, K. V. (2023). Extracellular vesicles: The next generation in gene therapy delivery. Molecular Therapy, 31(5), 1225-1230. https://doi.org/10.1016/j.ymthe.2023.01.021
Vancouver
Cecchin R, Troyer Z, Witwer K, Morris KV. Extracellular vesicles: The next generation in gene therapy delivery. Molecular Therapy. 2023;31(5):1225-1230. doi:10.1016/j.ymthe.2023.01.021
BibTeX
@article{Cecchin2023,
author = {Cecchin, Riccardo and Troyer, Zach and Witwer, Ken and Morris, Kevin V},
title = {Extracellular vesicles: The next generation in gene therapy delivery},
journal = {Molecular Therapy},
year = {2023},
volume = {31},
number = {5},
pages = {1225--1230},
doi = {10.1016/j.ymthe.2023.01.021}
}
EUVIMED